Advaxis Kick Starts Early-Stage Study For Prostate Cancer Immunotherapy

by Vandana Singh, Benzinga Editor

July 15, 2021 8:53 AM | 1 min read |

Advaxis Inc ADXS has initiated a Phase 1 study evaluating ADXS-504 in patients with recurrent prostate cancer.
The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504, Advaxis' off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.
The Phase 1 open-label dose-escalation study will evaluate the safety and tolerability of two dose levels of ADXS-504 monotherapy.
The study will also evaluate preliminary clinical and immune responses following treatment with ADXS-504 monotherapy.
Recently, the Company has announced a reverse merger agreement with privately-held Biosight Ltd.
Price Action: ADXS shares are up 3.7% at $0.45 during the premarket session on the last check Thursday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.